Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in Canada
Cancer Treatment and Research Communications · 2025
DOI: 10.1016/j.ctarc.2025.100896 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von William J Phillips und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins B-raf, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer Canada ULC.
Abstract (Originalsprache)
BACKGROUND: BRAF V600E mutations are identified in 10 % of metastatic colorectal cancer (mCRC) cases. In this project, we evaluated the clinicopathologic features and natural history of patients with BRAF mutant (BRAF-mt) mCRC prior to era of BRAF targeted therapy. METHODS: This is a retrospective project evaluating patients with diagnosed with mCRC with an identified BRAF V600E mutation between January 1, 2015 and December 31, 2021 seen at the Ottawa Hospital Cancer Centre prior to the approval of cetuximab and encorafenib in Canada. Demographic, clinical, and cancer characteristics were collected from the medical records. Outcomes of interest included overall survival (OS) and time to next therapy (TNT). RESULTS: 71 patients were included. The median age was 69 years, 37 (52 %) patients were females, and 19 (27 %) were mismatch repair deficient (dMMR). Median OS was 12.9 months with 21 (30 %) patients living greater than 2-years. Signet ring histology (HR=7.27, p < 0.001), peritoneal metastasis (HR=2.29, 0.003), distant lymphatic metastasis (HR=2.70, p < 0.001), brain metastasis (HR=2.86, p < 0.048) and metastatectomy (HR=0.17, p < 0.001) were associated with OS. Forty-six (65 %) patients received first-line systemic therapy, 14 (20 %) second-line and 2 (3 %) third-line. Median duration of therapy was 8.5 months for first-line, 5.5 months for second-line and 1.5 months for third-line. CONCLUSION: Real world data demonstrates that patients with BRAF-V600E mCRC have poor clinical outcomes with traditional systemic therapies. Only a minority of patients received second- or third-line systemic treatments, highlighting the importance of ongoing research evaluating incorporation of targeted therapy in first-line treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
- The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
- Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
- Eastern Ontario Regional Laboratory Association (EORLA), ON, Canada.
- The Ottawa Hospital Research Institute, Ottawa, ON, Canada; Eastern Ontario Regional Laboratory Association (EORLA), ON, Canada.
- Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON, Canada. Electronic address: rgoodwin@toh.ca.
Förderung
- Pfizer Canada ULC
Zitieren
APA
Phillips, W. J., Marginean, H., Alrehaili, M., Abdelrahim, A. A., Asmis, T., Vickers, M., Yeung, B., Lo, B., & Goodwin, R. (2025). Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in Canada. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.100896
Vancouver
Phillips WJ, Marginean H, Alrehaili M, Abdelrahim AA, Asmis T, Vickers M, et al. Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in Canada. Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2025.100896
BibTeX
@article{Phillips2025,
author = {Phillips, William J and Marginean, Horia and Alrehaili, Mohammad and Abdelrahim, Arwa Ahmed and Asmis, Tim and Vickers, Mike and Yeung, Benjamin and Lo, Bryan and Goodwin, Rachel},
title = {Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in Canada},
journal = {Cancer Treatment and Research Communications},
year = {2025},
doi = {10.1016/j.ctarc.2025.100896}
}
EUVIMED